Wyszuk. zaawans.

Tom 7, Nr 6 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-12-07

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 1114
Wyświetlenia/pobrania artykułu 2738
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Badania kontrolne po leczeniu najczęstszych nowotworów litych u dorosłych: zalecenia panelu ekspertów

Jacek Jassem1, Anna Kowalczyk1, Aleksander Biesiada23, Renata Duchnowska4, Rafał Dziadziuszko1, Agnieszka Mastalerz-Migas5, Andrzej Kawecki6, Maciej Krzakowski7, Piotr Potemski89, Piotr Rutkowski10, Piotr Wysocki11
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(6):440-465.

Streszczenie

Badania kontrolne po leczeniu onkologicznym stanowią niezbędny element całościowej opieki nad chorymi na nowotwory. Określenie ich optymalnego schematu ma istotne znaczenie kliniczne, organizacyjne i ekonomiczne. Istnieje niewiele prospektywnych badań klinicznych dotyczących badań kontrolnych, zatem zalecenia na ten temat opierają się najczęściej na retrospektywnych obserwacjach lub opiniach ekspertów. W 2014 roku ukazała się pierwsza w Polsce propozycja schematów badań kontrolnych po leczeniu najczęstszych nowotworów litych, przygotowana przez specjalistów w dziedzinie onkologii i medycyny rodzinnej. W niniejszej pracy przedstawiamy aktualizację tego opracowania z uwzględnieniem aktualnego piśmiennictwa oraz jakości dowodów naukowych.

Słowa kluczowe: nowotwory złośliweobserwacja po leczeniuzalecenia

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Jassem J, Duchnowska R, Kawecki A, et al. Badania kontrolne po leczeniu w najczęstszych nowotworach litych u dorosłych. Nowotwory. Journal of Oncology. 2014; 64(5): 415–435.
    CrossRef
  2. Appraisal of Guidelines for Research and Evaluation (AGREE). http://www.agreetrust.org (30.08.2022).
  3. Kearney PL, Watkins JM, Shirai K, et al. Salvage Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent Chemoradiotherapy Case Series and Review of the Literature. Mcgill J Med. 2011; 13(2): 29.
    PubMed
  4. Lee DH, Roh JL, Baek S, et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013; 149(4): 579–586.
    CrossRefPubMed
  5. Jassem J. Tobacco smoking after diagnosis of cancer: clinical aspects. Transl Lung Cancer Res. 2019; 8(Suppl 1): S50–S58.
    CrossRefPubMed
  6. Bała MM, Cedzyńska M, Balwicki Ł, et al. Wytyczne leczenia uzależnienia od nikotyny. Med Prakt. 2022: 22–40.
  7. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000; 110(3 Pt 2 Suppl 93): 1–18.
    CrossRefPubMed
  8. Oral Care Study Group. Evidence-based management strategies for oral complication from cancer treatment. MASCC/ISOO; 2011. www.mascc.org/isoo (30.08.2022).
  9. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Wersja 2.2022. www.nccn.org (30.08.2022).
  10. Manikantan K, Khode S, Dwivedi RC, et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev. 2009; 35(8): 744–753.
    CrossRefPubMed
  11. Simo R, Homer J. Follow-up of Head and Neck Cancers. Head and neck cancer: multidisciplinary management guidelines. ENT-UK, London 2011: 362–366.
  12. Louis D, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–1251.
    CrossRef
  13. Monroe CL, Travers S, Woldu HG, et al. Does Surveillance-Detected Disease Progression Yield Superior Patient Outcomes in High-Grade Glioma? World Neurosurg. 2020; 135: e410–e417.
    CrossRefPubMed
  14. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Wersja 1.2022. www.nccn.org (30.08.2022).
  15. Jo J, van den Bent MJ, Nabors B, et al. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas. Neuro Oncol. 2022; 24(7): 1035–1047.
    CrossRefPubMed
  16. Abdalla G, Hammam A, Anjari M, et al. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook. BJR Open. 2020; 2(1): 20200009.
    CrossRefPubMed
  17. Geßler F, Dützmann S, Quick J, et al. Is postoperative imaging mandatory after meningioma removal? Results of a prospective study. PLoS One. 2015; 10(4): e0124534.
    CrossRefPubMed
  18. Islim AI, Kolamunnage-Dona R, Mohan M, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. Neuro Oncol. 2020; 22(2): 278–289.
    CrossRefPubMed
  19. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e437S–e454S.
    CrossRefPubMed
  20. Lou F, Huang J, Sima CS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013; 145(1): 75–81; discussion 81.
    CrossRefPubMed
  21. Schmidt-Hansen M, Baldwin DR, Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol. 2012; 7(5): 821–824.
    CrossRefPubMed
  22. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190.
    CrossRefPubMed
  23. Nakamura R, Kurishima K, Kobayashi N, et al. Postoperative follow-up for patients with non-small cell lung cancer. Onkologie. 2010; 33(1-2): 14–18.
    CrossRefPubMed
  24. Crabtree TD, Puri V, Chen SB, et al. Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? J Thorac Cardiovasc Surg. 2015; 149(1): 45–52, 53.e1.
    CrossRefPubMed
  25. Srikantharajah D, Ghuman A, Nagendran M, et al. Is computed tomography follow-up of patients after lobectomy for non-small cell lung cancer of benefit in terms of survival? Interact Cardiovasc Thorac Surg. 2012; 15(5): 893–898.
    CrossRefPubMed
  26. Westeel V, Foucher P, Scherpereel A, et al. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(9): 1180–1188.
    CrossRefPubMed
  27. McMurry T, Stukenborg G, Kessler L, et al. More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival. Ann Surg. 2018; 268(4): 632–639.
    CrossRef
  28. Denis F, Lethrosne C, Pourel N, et al. Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. J Natl Cancer Inst. 2017; 109(9).
    CrossRefPubMed
  29. Sugiyama T, Hirose T, Hosaka T, et al. Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer. 2008; 59(2): 255–261.
    CrossRefPubMed
  30. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(5): 663–671.
    CrossRefPubMed
  31. Baudin E, Caplin M, Garcia-Carbonero R, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(4): 439–451.
    CrossRefPubMed
  32. Sinha S, Swift AJ, Kamil MA, et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol. 2020; 75(6): 423–432.
    CrossRefPubMed
  33. Falkson CB, Bezjak A, Darling G, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009; 4(7): 911–919.
    CrossRefPubMed
  34. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019; 9(9): CD002200.
    CrossRefPubMed
  35. Primrose JN, Perera R, Gray A, et al. FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014; 311(3): 263–270.
    CrossRefPubMed
  36. Argilés G, Tabernero J, Labianca R, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(10): 1291–1305.
    CrossRefPubMed
  37. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon cancer. Wersja 3.2022. www.nccn.org (30.08.2022).
  38. Meyerhardt JA, Mangu PB, Flynn PJ, et al. American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013; 31(35): 4465–4470.
    CrossRefPubMed
  39. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Rectal cancer. Wersja 1.2022. www.nccn.org (30.08.2022).
  40. Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv22–iv40.
    CrossRefPubMed
  41. Khatcheressian JL, Hurley P, Bantug E, et al. American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(7): 961–965.
    CrossRefPubMed
  42. Senkus E, Kyriakides S, Penault-Llorca F, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24(supl. 6): vi7–vi23.
  43. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2000(4): CD001768.
    CrossRefPubMed
  44. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994; 271(20): 1587–1592.
    CrossRefPubMed
  45. Goldhirsch A, Winer EP, Coates AS, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9): 2206–2223.
    CrossRefPubMed
  46. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006; 24(6): 848–855.
    CrossRefPubMed
  47. Jassem J, Krzakowski M, Bobek-Billewicz B, et al. Rak piersi. Onk Prakt Klin Edu. 2020; 6: 297–532.
  48. Lu W, de Bock GH, Schaapveld M, et al. The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer. 2011; 47(5): 676–682.
    CrossRefPubMed
  49. Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J. 2006; 12(1): 2–6.
    CrossRefPubMed
  50. Berg WA, Zhang Z, Cormack JB, et al. ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012; 307(13): 1394–1404.
    CrossRefPubMed
  51. Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol. 2012; 19(9): 3035–3041.
    CrossRefPubMed
  52. Barnsley GP, Grunfeld E, Coyle D, et al. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg. 2007; 120(5): 1125–1132.
    CrossRefPubMed
  53. Smid M, Wang Y, Zhang Yi, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68(9): 3108–3114.
    CrossRefPubMed
  54. Khan QJ, Reddy PS, Kimler BF, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010; 119(1): 111–118.
    CrossRefPubMed
  55. Rastelli AL, Taylor ME, Gao F, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011; 129(1): 107–116.
    CrossRefPubMed
  56. Głuszko P, Tłustochowicz W, Korkosz M. Choroby metaboliczne kości. In: Gajewski P, Korkosz M. ed. Interna Szczeklika 2021. Medycyna Praktyczna, Kraków 2021: 2165–2175.
  57. Kroenke CH, Chen WY, Rosner B, et al. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005; 23(7): 1370–1378.
    CrossRefPubMed
  58. Holmes M, Chen WY, Feskanich D, et al. Physical Activity and Survival After Breast Cancer Diagnosis. JAMA. 2005; 293(20): 2479.
    CrossRef
  59. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet. 2004; 363(9407): 453–455.
    CrossRef
  60. Zhao S, Chlebowski RT, Anderson GL, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014; 16(2): R30.
    CrossRefPubMed
  61. Moegele M, Buchholz S, Seitz S, et al. Vaginal Estrogen Therapy for Patients with Breast Cancer. Geburtshilfe Frauenheilkd. 2013; 73(10): 1017–1022.
    CrossRefPubMed
  62. Le Ray I, Dell'Aniello S, Bonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012; 135(2): 603–609.
    CrossRefPubMed
  63. Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, et al. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. Oncologist. 2020; 25(12): e1846–e1854.
    CrossRefPubMed
  64. Melisko ME, Goldman ME, Hwang J, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017; 3(3): 313–319.
    CrossRefPubMed
  65. Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017; 146(1): 3–10.
    CrossRefPubMed
  66. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Uterine Neoplasms. Wersja 1.2022. www.nccn.org (30.08.2022).
  67. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cervical cancer. Wersja 1.2022. www.nccn.org (30.08.2022).
  68. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. Wersja 4.2022. www.nccn.org (30.08.2022).
  69. Marth C, Landoni F, Mahner S, et al. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv72–iv83.
    CrossRefPubMed
  70. Ledermann JA, Raja FA, Fotopoulou C, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi24–vi32.
    CrossRefPubMed
  71. Colombo N, Preti E, Landoni F, et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi33–vi38.
    CrossRefPubMed
  72. Newton C, Nordin A, Rolland P, et al. British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU). Int J Gynecol Cancer. 2020; 30(5): 695–700.
    CrossRefPubMed
  73. Fung-Kee-Fung M, Dodge J, Elit L, et al. Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006; 101(3): 520–529.
    CrossRefPubMed
  74. Zola P, Ciccone G, Piovano E, et al. Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708). J Clinl Oncol. 2021; 39(15_suppl): 5506–5506.
    CrossRef
  75. Elit L, Fyles AW, Oliver TK, et al. Follow-Up for Women after Treatment for Cervical Cancer. Curr Oncol. 2010; 17(3): 65–69.
    CrossRef
  76. Zanagnolo V, Ming L, Gadducci A, et al. Surveillance procedures for patients with cervical carcinoma: a review of the literature. Int J Gynecol Cancer. 2009; 19(2): 194–201.
    CrossRefPubMed
  77. Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009; 112(1): 104–109.
    CrossRefPubMed
  78. Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol. 2005; 97(3): 828–833.
    CrossRefPubMed
  79. Tantipalakorn C, Robertson G, Marsden DE, et al. Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstet Gynecol. 2009; 113(4): 895–901.
    CrossRefPubMed
  80. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009; 19(3): 367–374.
    CrossRefPubMed
  81. Rustin GJ, van de, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376(9747): 1155–1163.
    CrossRefPubMed
  82. Scaletta G, Plotti F, Luvero D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017; 17(9): 827–839.
    CrossRefPubMed
  83. Bois Adu, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009; 115(6): 1234–1244.
    CrossRef
  84. du Bois A, Ewald-Riegler N, de Gregorio N, et al. Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer. 2013; 49(8): 1905–1914.
    CrossRefPubMed
  85. Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015; 51(5): 620–631.
    CrossRefPubMed
  86. Zanetta G, Rota S, Lissoni A, et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001; 81(1): 63–66.
    CrossRefPubMed
  87. Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist. 2009; 14(6): 591–600.
    CrossRefPubMed
  88. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003; 21(6): 1180–1189.
    CrossRefPubMed
  89. Gershenson DM. Management of ovarian germ cell tumor. J Clin Oncol. 2007; 25: 2938–2943.
  90. Shen S, Lepor H, Yaffee R, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 2005; 173(3): 777–780.
    CrossRefPubMed
  91. Eisenberg ML, Davies BJ, Cooperberg MR, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010; 57(4): 622–629.
    CrossRefPubMed
  92. Cheung R, Roach M, Hanks G, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4): 965–974.
    CrossRefPubMed
  93. Stamey T, Kabalin J, Mcneal J, et al. Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated Patients. J Urol. 1989; 141(5): 1076–1083.
    CrossRef
  94. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43(5): 649–659.
    CrossRefPubMed
  95. Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006; 64(4): 1140–1150.
    CrossRefPubMed
  96. Hancock S, Cox R, Bagshaw M. Prostate Specific Antigen After Radiotherapy for Prostate Cancer. J Urol. 1995: 1412–1417.
    CrossRef
  97. Oefelein M, Smith N, Carter M, et al. The Incidence of Prostate Cancer Progression with Undetectable Serum Prostate Specific Antigen in a Series of 394 Radical Prostatectomies. J Urol. 1995: 2128–2131.
    CrossRef
  98. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001; 166(1): 63–67.
    PubMed
  99. LAM J, SHVARTS O, LEPPERT J, et al. POSTOPERATIVE SURVEILLANCE PROTOCOL FOR PATIENTS WITH LOCALIZED AND LOCALLY ADVANCED RENAL CELL CARCINOMA BASED ON A VALIDATED PROGNOSTIC NOMOGRAM AND RISK GROUP STRATIFICATION SYSTEM. Journal of Urology. 2005; 174(2): 466–472.
    CrossRef
  100. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97(7): 1663–1671.
    CrossRefPubMed
  101. Karakiewicz PI, Briganti A, Chun FKH, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25(11): 1316–1322.
    CrossRefPubMed
  102. Bellmunt J, Orsola A, Leow JJ, et al. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii40–iii48.
    CrossRefPubMed
  103. Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer. European Urology. 2011; 60: 304–319.
  104. Hakenberg OW, Compérat EM, Minhas S, et al. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015; 67(1): 142–150.
    CrossRefPubMed
  105. Francken AB, Hoekstra HJ. Follow-up of melanoma patients: the need for evidence-based protocols. Ann Surg Oncol. 2009; 16(4): 804–805.
    CrossRefPubMed
  106. Fields RC, Coit DG. Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am. 2011; 20(1): 181–200.
    CrossRefPubMed
  107. Scally CP, Wong SL. Intensity of follow-up after melanoma surgery. Ann Surg Oncol. 2014; 21(3): 752–757.
    CrossRefPubMed
  108. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995; 274(21): 1703–1705.
    PubMed
  109. Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12): 1884–1901.
    CrossRefPubMed
  110. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Wersja 3.2022. www.nccn.org (30.08.2022).
  111. Francken A, Bastiaannet E, Hoekstra H. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005; 6(8): 608–621.
    CrossRef
  112. Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007; 14(6): 1924–1933.
    CrossRefPubMed
  113. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003; 21(3): 520–529.
    CrossRefPubMed
  114. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009; 16(4): 941–947.
    CrossRefPubMed
  115. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010; 28(18): 3042–3047.
    CrossRefPubMed
  116. Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014; 259(6): 1215–1222.
    CrossRefPubMed
  117. Turner RM, Bell KJL, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011; 29(35): 4641–4646.
    CrossRefPubMed
  118. Tsao H, Feldman M, Fullerton JE, et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol. 2004; 140(1): 67–70.
    CrossRefPubMed
  119. Autier P, Coebergh JW, Boniol M, et al. Management of melanoma patients: benefit of intense follow-up schedule is not demonstrated. J Clin Oncol. 2003; 21(19): 3707; author reply 3707–8.
    CrossRefPubMed
  120. Einwachter-Thompson J, MacKie RM. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol. 2008; 159(2): 337–341.
    CrossRefPubMed
  121. Moncrieff MD, Underwood B, Garioch JJ, et al. The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years. Ann Surg Oncol. 2020; 27(11): 4109–4119.
    CrossRefPubMed
  122. Deckers EA, Hoekstra-Weebers JE, Damude S, et al. The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. Ann Surg Oncol. 2020; 27(5): 1407–1417.
    CrossRefPubMed
  123. Park TS, Phan GQ, Yang JC, et al. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol. 2017; 24(4): 947–951.
    CrossRefPubMed
  124. Rutkowski P, Lugowska I. Follow-up in melanoma patients. Memo. 2014; 7(2): 83–86.
    CrossRefPubMed
  125. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011; 103(2): 129–142.
    CrossRefPubMed
  126. Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006; 142(4): 433–438.
    CrossRefPubMed
  127. Schuurman MS, de Waal AC, Thijs EJM, et al. Risk factors for second primary melanoma among Dutch patients with melanoma. Br J Dermatol. 2017; 176(4): 971–978.
    CrossRefPubMed
  128. Youlden DR, Youl PH, Soyer HP, et al. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010. JAMA Dermatol. 2014; 150(5): 526–534.
    CrossRefPubMed
  129. Lallas A, Apalla Z, Kyrgidis A, et al. Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring. J Am Acad Dermatol. 2020; 82(2): 398–406.
    CrossRefPubMed
  130. Salama AKS, de Rosa N, Scheri RP, et al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One. 2013; 8(3): e57665.
    CrossRefPubMed
  131. Cool P, Grimer R, Rees R. Surveillance in patients with sarcoma of the extremities. Eur J Surg Oncol. 2005; 31(9): 1020–1024.
    CrossRefPubMed
  132. Goel A, Christy MEL, Virgo KS, et al. Costs of follow-up after potentially curative treatment for extremity soft-tissue sarcoma. Int J Oncol. 2004; 25(2): 429–435.
    PubMed
  133. Gerrand CH, Billingham LJ, Woll PJ, et al. Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom. Sarcoma. 2007; 2007: 34128.
    CrossRefPubMed
  134. Casali PG, Blay JY, Abecassis N, et al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org, ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(11): 1348–1365.
    CrossRefPubMed
  135. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Soft Tissue Sarcoma. Wersja 2.2022. www.nccn.org (30.08.2022).
  136. Grimer R, Judson I, Peake D, et al. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010; 2010: 506182.
    CrossRefPubMed
  137. Ruka W, Rutkowski P, Krzakowski M, et al. Mięsaki tkanek miękkich u dorosłych– zasady postępowania diagnostyczno-terapeutycznego. Nowotwory J Oncol. 2010; 60: 55–65.
  138. Sakata K, Beitler AL, Gibbs JF, et al. How surgeon age affects surveillance strategies for extremity soft tissue sarcoma patients after potentially curative treatment. J Surg Res. 2002; 108(2): 227–234.
    CrossRefPubMed
  139. Chou YS, Liu CY, Chen WM, et al. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival. J Surg Oncol. 2012; 106(2): 155–161.
    CrossRefPubMed
  140. Geel Av, Pastorino U, Jauch K, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996; 77(4): 675–682, doi: 10.1002/(sici)1097-0142(19960215)77:4<675::aid-cncr13>3.0.co;2-y.
  141. Patel SR, Zagars GK, Pisters PWT. The follow-up of adult soft-tissue sarcomas. Semin Oncol. 2003; 30(3): 413–416.
    CrossRefPubMed
  142. Casson A, Putnam J, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer. 1992; 69(3): 662–668, doi: 10.1002/1097-0142(19920201)69:3<662::aid-cncr2820690311>3.0.co;2-i.
  143. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993; 218(6): 705–712.
    CrossRefPubMed
  144. Whooley BP, Gibbs JF, Mooney MM, et al. Primary extremity sarcoma: what is the appropriate follow-up? Ann Surg Oncol. 2000; 7(1): 9–14.
    CrossRefPubMed
  145. Whooley BP, Mooney MM, Gibbs JF, et al. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol. 1999; 17(1): 83–87, doi: 10.1002/(sici)1098-2388(199907/08)17:1<83::aid-ssu11>3.0.co;2-w.
    PubMed
  146. Puri A, Gulia A, Hawaldar R, et al. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res. 2014; 472(5): 1568–1575.
    CrossRefPubMed
  147. Choi H, Varma DG, Fornage BD, et al. Soft-tissue sarcoma: MR imaging vs sonography for detection of local recurrence after surgery. AJR Am J Roentgenol. 1991; 157(2): 353–358.
    CrossRefPubMed
  148. Arya S, Nagarkatti DG, Dudhat SB, et al. Soft tissue sarcomas: ultrasonographic evaluation of local recurrences. Clin Radiol. 2000; 55(3): 193–197.
    CrossRefPubMed
  149. Briccoli A, Galletti S, Salone M, et al. Ultrasonography is superior to computed tomography and magnetic resonance imaging in determining superficial resection margins of malignant chest wall tumors. J Ultrasound Med. 2007; 26(2): 157–162.
    CrossRefPubMed
  150. Labarre D, Aziza R, Filleron T, et al. Detection of local recurrences of limb soft tissue sarcomas: is magnetic resonance imaging (MRI) relevant? Eur J Radiol. 2009; 72(1): 50–53.
    CrossRefPubMed
  151. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology. 1994; 190(1): 263–268.
    CrossRefPubMed
  152. Brennan MF. Follow-up is valuable and effective: true, true and unrelated? Ann Surg Oncol. 2000; 7(1): 2–3.
    CrossRefPubMed
  153. Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(1): 20–33.
    CrossRef
  154. Rutkowski P, Ługowska I, Fijuth J, et al. Soft tissue sarcomas in adults. Oncol Clin Pract. 2017; 13: 181–201.
    CrossRef
  155. Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011; 117(21): 4916–4924.
    CrossRefPubMed
  156. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12): 1265–1272.
    CrossRefPubMed
  157. Rutkowski P, Świtaj T, Mazurkiewicz T, et al. Bone sarcomas. Oncol Clin Pract. 2018; 14: 115–128.
    CrossRef
  158. Strauss SJ, Frezza AM, Abecassis N, et al. ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(12): 1520–1536.
    CrossRefPubMed
  159. Lin PP, Patel S. Bone sarcoma. Springer, New York 2013.
  160. Grimer R, Athanasou N, Gerrand C, et al. UK Guidelines for the Management of Bone Sarcomas. Sarcoma. 2010; 2010: 317462.
    CrossRefPubMed
  161. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Bone Cancer. Wersja 1.2023. www.nccn.org (30.08.2022).
  162. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006; 24(3): 476–483.
    CrossRefPubMed
  163. Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol. 2000; 22(4): 321–329.
    CrossRefPubMed
  164. Aksnes LH, Bauer H, Dahl AA, et al. Health status at long-term follow-up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: A Scandinavian sarcoma group study. Pediatr Blood Cancer. 2009; 53(1): 84–89.
    CrossRef
  165. Langer T, Stöhr W, Paulides M, et al. Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr. 2005; 217(3): 176–181.
    CrossRefPubMed
  166. Goryń T, Szostakowski B, Pieńkowski A, et al. Long-term follow-up in adults with extremity osteosarcoma: comparison of different surgical procedures - single-center experience. Contemp Oncol (Pozn). 2019; 23(4): 234–238.
    CrossRefPubMed
  167. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor. National Academies Press, Washington 2005.
  168. Lafata J, Simpkins J, Schultz L, et al. Routine Surveillance Care After Cancer Treatment With Curative Intent. Med Care. 2005; 43(6): 592–599.
    CrossRef
  169. McCabe MS, Partridge AH, Grunfeld E, et al. Risk-based health care, the cancer survivor, the oncologist, and the primary care physician. Semin Oncol. 2013; 40(6): 804–812.
    CrossRefPubMed
  170. Howell D, Hack TF, Oliver TK, et al. Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv. 2012; 6(4): 359–371.
    CrossRefPubMed
  171. Radecka B, Streb J. Czy kontrolę po leczeniu onkologicznym powinien prowadzić onkolog? Nowotwory. 2016; 1: 274–277.
  172. Halpern MT, Viswanathan M, Evans TS, et al. Models of Cancer Survivorship Care: Overview and Summary of Current Evidence. J Oncol Pract. 2015; 11(1): e19–e27.
    CrossRefPubMed
  173. Del Gi, Bondy SJ, Maarten S. Physician care of cancer patients: ICES atlas. Ontario 2006: 162–174.
  174. McWhinney IR, Hoddinott SN, Bass MJ, et al. Role of the family physician in the care of cancer patients. Can Fam Physician. 1990; 36: 2183–2186.
    PubMed
  175. Dood RL, Zhao Y, Armbruster SD, et al. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018; 4(11): 1519–1526.
    CrossRefPubMed
  176. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017; 70(20): 2536–2551.
    CrossRefPubMed
  177. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press, Washington 2006.
  178. Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr. 2010; 2010(40): 25–30.
    CrossRefPubMed
  179. Krajowy Rejestr Nowotworów. http://onkologia.org.pl/ (30.08.2022).
  180. Nekhlyudov L, Aziz NM, Lerro C, et al. Oncologists' and primary care physicians' awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract. 2014; 10(2): e29–e36.
    CrossRefPubMed
  181. Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008; 26(7): 1073–1079.
    CrossRefPubMed
  182. Grunfeld E, Mant D, Vessey MP, et al. Specialist and general practice views on routine follow-up of breast cancer patients in general practice. Fam Pract. 1995; 12(1): 60–65.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna